Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044238 | 1.00 | SERPINE1 (0.54) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL18585793 | 0.85 | SERPINE1 (0.59) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL16585686 | 0.85 | SERPINE1 (0.59) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL18585722 | 0.84 | SERPINE1 (0.58) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL17157078 | 0.83 | SERPINE1 (0.54) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL18585433 | 0.82 | SERPINE1 (0.59) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL18585589 | 0.79 | SERPINE1 (0.63) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL3228891 | 0.79 | SERPINE1 (0.55) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL20578289 | 0.79 | SERPINE1 (0.55) | SERPINE1PTPN2PTPN1PTPN11ESR1 | |
| SCHEMBL11986809 | 0.77 | SERPINE1 (0.46) | SERPINE1PTPN2PTPN1PTPN11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12305208-B2 | Method for producing sedoheptulose | NAGASE & CO., LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20230407354-A1 | METHOD FOR PRODUCING SEDOHEPTULOSE | NAGASE & CO., LTD. (JP) | 2023-12-21 | — | — | US | disclosed |
| US-11781165-B2 | Method for producing sedoheptulose | NAGASE & CO., LTD. (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-115364112-A | Use of sedoheptulose for preventing or treating inflammation | C7糖果有限责任公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-113679047-A | Use of sedoheptulose as a nutritional supplement | C7糖果有限责任公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20210246475-A1 | METHOD FOR PRODUCING SEDOHEPTULOSE | NAGASE & CO., LTD. (JP) | 2021-08-12 | — | — | US | disclosed |
| US-11026443-B2 | Use of sedoheptulose as a nutritional supplement | C7 SUGAR GMBH (AT) | 2021-06-08 | — | — | US | disclosed |
| EP-3786303-A1 | METHOD FOR PRODUCING SEDOHEPTULOSE | Nagase & Co., Ltd. (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-2976088-B1 | USE OF SEDOHEPTULOSE AS A NUTRITIONAL SUPPLEMENT | C7 SUGAR GMBH (AT) | 2021-01-27 | — | — | EP | disclosed |
| EP-3747444-A2 | USE OF SEDOHEPTULOSE AS A NUTRITIONAL SUPPLEMENT | C7 SUGAR GMBH (AT) | 2020-12-09 | — | — | EP | disclosed |
| EP-2976088-A1 | USE OF SEDOHEPTULOSE AS A NUTRITIONAL SUPPLEMENT | Medizinische Universität Wien (AT) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976089-A1 | USE OF SEDOHEPTULOSE FOR PREVENTION OR TREATMENT OF INFLAMMATION | Medizinische Universität Wien (AT) | 2016-01-27 | — | — | EP | disclosed |
| CN-105283188-A | Use of sedoheptulose for preventing or treating inflammation | UNIV WIEN MED | 2016-01-27 | — | — | CN | disclosed |
| US-20150197536-A1 | COMPOUNDS REDUCING THE PRODUCTION OF SORBITOL IN THE EYE AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-16 | — | — | US | disclosed |
| WO-2014147214-A1 | USE OF SEDOHEPTULOSE FOR PREVENTION OR TREATMENT OF INFLAMMATION | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147213-A1 | USE OF SEDOHEPTULOSE AS A NUTRITIONAL SUPPLEMENT | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2014-09-25 | — | — | WO | disclosed |
| EP-2781219-A1 | Use of sedoheptulose for prevention or treatment of inflammation | Medizinische Universität Wien (AT) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781218-A1 | Use of sedoheptulose as a nutritional supplement | Medizinische Universität Wien (AT) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014022291-A1 | COMPOUNDS REDUCING THE PRODUCTION OF SORBITOL IN THE EYE AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-02-06 | — | — | WO | disclosed |
| JP-2011231036-A | DIABETIC COMPLICATION AMELIORATING AGENT | ISKRA INDUSTRY CO LTD | 2011-11-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197536-A1 | COMPOUNDS REDUCING THE PRODUCTION OF SORBITOL IN THE EYE AND METHODS OF USING THE SAME | SORD, ALDOA, SLC2A1 | SERPINE1 231/4885PTPN2 4286/4885PTPN1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.